| Brenzavvy (bexagliflozin) / TheracosBio |
NCT00854113: Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers |
|
|
| Completed | 1 | 78 | US | EGT0001474, Human SGLT2 inhibitor, Placebo | Theracos | Safety and Tolerability of EGT0001474 in Healthy Volunteers | 07/09 | 07/09 | | |
NCT00924053: Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes |
|
|
| Completed | 1 | 24 | US | EGT0001474, Human SGLT2 inhibitor, Placebo | Theracos | Diabetes Mellitus Type 2 | 07/09 | 07/09 | | |
NCT02820298: Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects |
|
|
| Completed | 1 | 25 | US | Bexagliflozin, EGT0001442, EGT0001474 | Theracos | Type 2 Diabetes Mellitus | 08/16 | 08/16 | | |
NCT02956044: Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin |
|
|
| Completed | 1 | 54 | US | Bexagliflozin, Metformin, Glimepiride, Sitagliptin | Theracos | Type2 Diabetes Mellitus | 03/17 | 03/17 | | |
NCT03167411: Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection |
|
|
| Completed | 1 | 20 | US | Bexagliflozin, Exenatide Injection, Byetta® | Theracos | Type2 Diabetes Mellitus | 06/17 | 06/17 | | |
NCT03197324: Bexagliflozin Drug/Drug Interaction Study With Digoxin |
|
|
| Completed | 1 | 20 | US | Bexagliflozin, EGT0001442, EGT0001474, Digoxin | Theracos | Type2 Diabetes Mellitus | 09/17 | 09/17 | | |
NCT03296800: Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects |
|
|
| Completed | 1 | 48 | US | Bexagliflozin, EGT0001442, EGT0001474, Probenecid, Probalan, Rifampin, Rifadin, Verapamil, Verelan | Theracos | Type 2 Diabetes Mellitus | 12/17 | 12/17 | | |
NCT03417076: Absolute Bioavailability Study With Bexagliflozin |
|
|
| Withdrawn | 1 | 0 | US | Bexagliflozin, EGT0001442, EGT0001474 | Theracos | Type 2 Diabetes Mellitus | 09/18 | 09/18 | | |
NCT03557658: Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment |
|
|
| Completed | 1 | 16 | US | Bexagliflozin | Theracos | Type2 Diabetes Mellitus | 12/18 | 12/18 | | |
NCT05369078: Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects |
|
|
| Recruiting | 1 | 16 | RoW | THR-1442 20mg Single dose, THR-1442 20mg Multiple dose group | Newsoara Biopharma Co., Ltd. | T2DM (Type 2 Diabetes Mellitus) | 05/22 | 05/22 | | |
